Amgen's bone drug as good as Zometa in patients with solid tumours
This article was originally published in Scrip
Executive Summary
Amgen's denosumab is as effective as Novartis's Zometa for the treatment of bone metastases in patients with solid tumours, show preliminary results of a Phase III trial.